Financials

News Discussions Technicals Seasonals

DEX fundamentals

Overview Statements Statistics Dividends Earnings Revenue

Key facts

—

—

—

—

—

—

—

—

About

Dextech Medical AB engages in the provision of research and development of drug candidates for urological oncology. It focuses on the treatment of prostate cancer and non-malignant diseases. Its product portfolio includes OsteoDex, SomaDex, CatDex, and PSMADex. The company was founded by Anders R. Holmberg and Sten Nilsson on April 21, 2004 and is headquartered in Uppsala, Sweden.

Valuation

Fundamental metrics to determine fair value of the stock

Summary

No data available

There's currently no market capitalization, revenue or net income data to show.

Valuation ratios

Growth and Profitability

Company’s recent performance and margins

Dividends

Dividend yield, history and sustainability

No dividends

DEX has never paid dividends and has no current plans to do so.

Financial health

Financial position and solvency of the company